AMR report depicts industry commitment

Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.

Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.

Adrian van den Hoven, director general of Medicines for Europe, said the report was a “key milestone in cementing industry...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin